Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
Showing public results only.
Q1 2026 revenue beat, raised revenue guidance, and the first sixth-generation 256-qubit system sale. The proof gate is RPO conversion, organic revenue growth, and adjusted EBITDA loss discipline.
OpenRevvity is trying to prove the post-spin model can protect margins while faster life-science competitors chase growth.
OpenJoby needs certification progress to arrive before liquidity concerns dominate the air-taxi story.
OpenJoby has an ambitious air-taxi network vision, but the financial runway comes before scale.
OpenIonQ needs to prove its quantum advantage can survive competition from larger tech platforms with deeper budgets.
OpenIonQ benefits from quantum-computing excitement, but investors need to separate scientific progress from commercial revenue.
OpenInfleqtion has a clean quantum identity, record Q1 revenue, and a proposed $100M federal tailwind, but the business still needs revenue scale and operating-loss discipline.
OpenHims & Hers expanded its subscriber benefits bundle to ten partner brands. The update is not a direct revenue story yet; it is a retention, churn, and marketing-efficiency proof test.
OpenHIMS Q1 met the revenue test and raised revenue guidance, but lower margins and reduced adjusted EBITDA guidance keep the thesis conditional.
OpenHims is using GLP-1 weight loss to expand the platform, but the quality test is retention and cash flow.
OpenHims & Hers completed the Eucalyptus acquisition on June 2, 2026. The close upgrades the scale story, but the real proof still has to show up in international revenue mix, retention, margins, and cash flow.
OpenHims & Hers opened a Canada generic semaglutide path and closed $402.5M of zero-coupon convertible debt. The update turns HIMS into a global expansion versus dilution proof test.
OpenGinkgo has moved from broad synthetic-biology promise toward a harder profitability test.
OpenBitMine priced an upsized preferred-stock deal, and the real question is whether ETH treasury growth can beat a new preferred dividend claim that sits ahead of common shareholders.
OpenBMNR said crypto plus cash plus other holdings totaled twelve point three billion dollars as of May 25, 2026. The proof gate is ETH per share, staking yield, cash runway, and NAV transparency.
OpenBio-Rad has diagnostics exposure, but the market may be questioning whether the segment deserves a peer-growth multiple.
OpenBigBear.ai's Q1 2026 backlog and gross margin improved, but the deep dive keeps the proof gate on revenue conversion, adjusted EBITDA, and operating cash flow.
OpenAgilent's CrossLab segment is becoming the quiet efficiency layer for regulated pharma labs: services, consumables, software, automation, and asset monitoring. The proof gate is whether CrossLab can keep growing while margin stays strong.
OpenYum China reported FY2025 revenue of $11.8 billion and Q1 2026 revenue of $3.3 billion. The thesis depends on same-store demand, restaurant expansion, delivery economics, China consumer conditions, margin control and capex discipline.
OpenKinder Morgan reported 2025 revenue of $15.20 billion, operating income of $4.72 billion and operating cash flow of $5.92 billion. The Coverage Bootstrap question is whether natural-gas infrastructure cash flow can keep funding dividends and projects without l
Open